ABVC BIOPHARMA, INC.(ABVC)— Stock Profile, AI Score & Financials
Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
ABVC BIOPHARMA, INC. (ABVC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ABVC at 10.4/100 on a 32-signal composite quality model, placing it at rank #2,909 of 2,960 stocks — the bottom half of the AI-ranked universe. Top institutional holders of ABVC by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, GEODE CAPITAL MANAGEMENT, VANGUARD FIDUCIARY, based on the most recent SEC filings. ABVC trades on the Nasdaq exchange and files with the SEC under CIK 1173313. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABVC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ABVC BIOPHARMA, INC. directly from SEC EDGAR.
AI Quality Score
10.4/100
AI Rank
#2,909
Net Income
$-736.9K
ABVC key financials by period
ABVC BIOPHARMA, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$296.0K
$-7.9M
—
FY 2024
10-K
$509.6K
$-4.9M
—
FY 2023
10-K
$152.4K
$-7.8M
—
FY 2022
10-K
$969.8K
$-16.4M
—
FY 2021
10-K
$355.8K
$-12.8M
—
FY 2020
10-K
$483.0K
$-10.6M
—
Institutions holding ABVC
Institutional investors reporting a position in ABVC BIOPHARMA, INC. on SEC Form 13F.
